Polylysine-Containing Hydrogel Formulation of Fuzapladib, Inhibitor of Leukocyte-Function Associated Antigen-1 (LFA-1) Activation, for Sustained Release

Polylysine-Containing Hydrogel Formulation of Fuzapladib, Inhibitor of Leukocyte-Function Associated Antigen-1 (LFA-1) Activation, for Sustained Release

The aim of the present study was to develop an injectable hydrogel (HG) formulation of fuzapladib sodium (FZP), an animal drug for acute pancreatitis (AP), with the use of polyethyleneoxide (PEO) and polylysine (pLys), a cationic polymer. A mixture of pLys and FZP was added to PEO to prepare an HG f...

Full description

Bibliographic Details
Main Authors: Koji Higuchi, Kohei Yamada, Tsubasa Kihara, Keisuke Makino, Kenta Sasaki, Takeshi Shindo, Hiroshi Shikama, Hideyuki Sato, Satomi Onoue
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Molecules
Subjects:
acute pancreatitis
fuzapladib
hydrogel
polylysine
sustained release
Online Access:https://www.mdpi.com/1420-3049/28/14/5325

Internet

https://www.mdpi.com/1420-3049/28/14/5325

Similar Items